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Abstract
The aim of this study was to evaluate the mutagenicity (clastogenicity/aneugenicity) of a glycolic extract of Ziziphus
joazeiro bark (GEZJ) by the micronucleus assay in mice bone marrow. Antimutagenic activity was also assessed us-
ing treatments associated with GEZJ and doxorubicin (DXR). Mice were evaluated 24-48 h after exposure to positive
(N-nitroso-N-ethylurea, NEU - 50 mg.kg-1 and DXR - 5 mg.kg-1) and negative (150 mM NaCl) controls, as well as treat-
ment with GEZJ (0.5-2 g.kg-1), GEZJ (2 g.kg-1) + NEU and GEZJ (2 g.kg-1) + DXR. There were no significant differ-
ences in the frequencies of micronucleated polychromatic erythrocytes in mice treated with GEJZ and GEJZ + DXR
compared to the negative controls, indicating that GEZJ was not mutagenic. Analysis of the polychromatic:nor-
mochromatic erythrocyte ratio revealed significant differences in the responses to doses of 0.5 g.kg-1 and 1-2 g.kg-1
and the positive control (NEU). These results indicated no systemic toxicity and moderate toxicity at lower and higher
doses of GEZJ. The lack of mutagenicity and systemic toxicity in the antimutagenic assays, especially for treatment
with GEZJ + DXR, suggested that phytochemical compounds in Z. joazeiro bark attenuated DXR-induced muta-
genicity and the moderate systemic toxicity of a high dose of Z. joazeiro bark (2 g.kg-1). Further studies on the
genotoxicity of Z. joazeiro extracts are necessary to establish the possible health risk in humans and to determine the
potential as a chemopreventive agent for therapeutic use.
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Introduction
Many species of medicinal plants, such as Amburana
cearensis, Anadenanthera colubrina, Mentha x villosa,
Myracrodruon urundeuva, Plectranthus amboinicus, Ruta
graveolens, Ximenia americana and Ziziphus joazeiro, are
widely used by communities in the Brazilian Caatinga to
treat a large spectrum of clinical conditions ranging from
diseases requiring palliative care to general aches, e.g.,
bronchitis, sinusitis, rhinitis, nasal congestion, headaches,
flu, fever, expectorant, colic, hypertension, thrombosis, in-
digestion, intestinal dysfunction, liver and kidney prob-
lems, infectious and inflammatory processes and pain in
general (Cartaxo et al., 2010). Ziziphus joazeiro Mart.
(Rhamnaceae) is a native Brazilian tree resistant to dry en-
vironments (Cartaxo et al., 2010). This species is an impor-
tant source of water and food for animals in arid habitats
(Braga, 1960; Cruz, 1985; Nunes et al., 1987).
A phytochemical analysis of Z. joazeiro Mart. has
shown that the leaf epicuticular wax is rich in n-alkanes
(78.6%), very efficient compounds for impermeabilizing
the leaf surface, and triterpenoids (Oliveira et al., 2003). A
similar analysis of a dichloromethane extract of Z. joazeiro
Mart. bark identified triterpenoids with weak antibacterial
activity (e.g., betulinic, alphitolic and ursolic acids) and re-
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markable activity against Staphylococcus epidermidis
[e.g., betulinic acid ester derivatives such as 7-(4-
hydroxy-benzoyloxy), 7-(4-hydro-3-methoxy-benzoylo-
xy) and 27-(4-hydroxy-3-methoxy-benzoyloxy)] (Schuhly
et al., 1999). Ziziphus joazeiro Mart. bark also contains an
abundance of saponins that have been used as toothpastes,
with aqueous extracts showing antimicrobial action against
bacteria (planktonic cells and artificial biofilms) related to
dental caries and periodontal diseases (Alviano et al.,
2008). Other popular therapeutic applications of Z. joazeiro
Mart. include the treatment of dandruff, rheumatism, flu,
fever, chronic bronchitis, gastric ulcers, indigestion, heart-
burn and headaches (Schuhly et al., 1999; Cartaxo et al.,
2010). In addition, experimental studies have identified po-
tential antifungal (Cruz et al., 2007), antibacterial (Schuhly
et al., 1999; Alviano et al., 2008; Leal et al., 2010), antioxi-
dant (Alviano et al., 2008) and antipyretic (Nunes et al.,
1987) activities, as well as low toxicity (Alviano et al.,
2008).
Biologically active compounds have been recognized
for their pharmacological properties, but many of them are
of limited therapeutic use because of their toxicological,
carcinogenic and mutagenic properties (Ames, 1983;
Konstantoupoulou et al., 1992; Tavares, 1996). The analy-
sis of genotoxicity is a major aspect of drug development
since most pharmaceutical companies evaluate the poten-
tial of a new therapeutic agent based on its genotoxicity in
vitro and in vivo (Purves et al., 1995). In this context, the
screening of popularly used plants and their isolated com-
ponents for mutagenic activity is necessary and important
for establishing adequate control measures. This screening
can also provide insights into the mechanisms involved in
the biological effects of plants used as therapeutic agents
(Varanda, 2006).
As far as genotoxicity studies are concerned, the in
vivo micronucleus (MN) assay in rodent bone marrow is a
crucial part of the battery of tests used to identify hazardous
mutagens (Mateuca et al., 2006). This assay is especially
suited for assessing mutagenic hazards because it contem-
plates various factors, such as in vivo metabolism, phar-
macokinetics and DNA repair mechanisms, even though
these processes vary among species and tissues and have
different genetic endpoints (OECD, 1997a,b; Ribeiro et al.,
2003). Since bone marrow erythroblasts develop into poly-
chromatic erythrocytes (PCEs), i.e., cells generated by ex-
trusion of the main nucleus, micronuclei may remain in an
otherwise anucleated cytoplasm. Consequently, the fre-
quency of micronucleated polychromatic erythrocytes
(MNPCEs) has been the principal endpoint for MN assays.
The measurement of MNPCEs in peripheral blood is possi-
ble in any species in which the spleen does not remove
micronucleated erythrocytes, or that is sufficiently sensi-
tive to agents that cause structural or numerical chromo-
somal aberrations. An increase in the frequency of
MNPCEs in treated animals, i.e., a positive result, indicates
that a substance can cause the formation of micronuclei
through chromosomal damage or damage to the mitotic ap-
paratus of erythroblasts. On the other hand, a negative re-
sult implies that the test substance does not cause micro-
nucleus formation in immature erythrocytes. The number
of normochromatic erythrocytes (NCEs) in peripheral
blood that contain micronuclei for a given number of ma-
ture erythrocytes can also be used as the endpoint of this as-
say (OECD, 1997c; Ribeiro et al., 2003). Several studies
have used the mammalian in vivo MN assay to understand
the mutagenic effects induced by phytotherapeutics and
foods (Indart et al., 2007; Venkatesh et al., 2007; Chan-
drasekaran et al., 2011; Silva et al., 2011; Alves et al.,
2012).
Although several studies have examined the potential
therapeutic effectiveness of Z. joazeiro Mart., there has
been no systematic investigation of the genotoxic and
mutagenic effects of this plant. In this work, we examined
the mutagenic effects of a glycolic extract of Z. joazeiro
Mart. bark as part of a wider study on the genotoxic poten-
tial of herbal extracts. The effect of the maximum permissi-
ble concentration of Z. joazeiro Mart. on the mutagenicity
of doxorubicin (DXR) in mouse bone marrow, i.e., its
antimutagenic activity, was also examined.
Material and Methods
Raw material and sample preparation
A glycolic extract of Z. joazeiro bark (GEZJ) was
purchased commercially and stored according to the manu-
facturer’s recommendations (AKSY Comercial Ltda., São
Bernardo do Campo, SP, Brazil). Aliquots (1.5 L) of this
extract were submitted to solvent removal proceedings by
rotary evaporation (40 rpm) (Rotavapor model R-215) cou-
pled to a bath heating system maintained at 50-60 °C (Bath
Heating model B-491), a vacuum pump (vacuum of
500 mm Hg; Vacuum Pump V-700 with Automatic Vac-
uum Controller V-855), a water recirculator (Recirculator
Chiller F-100) and an evaporation bottle (Büchi Labor-
technik AG, Switzerland). The final product was trans-
ferred to a 1 L reaction bottle (SCHOTT® DURAN®) and
kept at -20 °C for 24 h in order to evaluate the freezing of
the final product and the efficacy of solvent evaporation
(Agência Nacional de Vigilância Sanitária (ANVISA)
(2010)). Aliquots (40 mL) of this final product were trans-
ferred to penicillin-type glass vials (50 mL) and lyophilized
(Lyophilizer model Alpha 1-2 LDPlus, Martin Christ
Gefriertrocknungsanlagen GmbH, Germany) and the dry
mass were measured (Electronic Analytical Balance
AUW-220D, Shimadzu Corp., Kyoto, Japan). Aqueous so-
lutions of the lyophilized product were prepared in type 1
water at twice the final concentration, sterilized by filtra-
tion (Millipore Corporation, hydrophilic Durapore® PVDF,
0.22 m,  47 mm, cat. no. GVWP 047 00) and stored in
sterile polypropylene tubes (50 mL) at -70 °C until used.
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In vivo assays
Healthy, heterogeneous, young adult male and female
Swiss mice (Unib:SW) 7-12 weeks old (pubescent period)
weighing 30-40 g (weight variation among mice of each
sex was < 20% of the mean weight) were provided by
CEMIB (Centro Multidisciplinar para Investigação Bioló-
gica - UNICAMP) and erythrocytes from the bone marrow
of these mice were used in the MN assay (Collaborative
Study Group for the Micronucleus Test (CSGMT), 1986;
Chorilli et al., 2007).
Animals of the same sex were housed in polypropy-
lene boxes in an air-conditioned environment to 22  3 °C,
with a relative air humidity of 50%  20% and a 12 h
light/dark cycle. The mice were fed commercial rodent
chow (Purina® Labina, Nestlé Purina Pet Care Company)
and water ad libitum, and were acclimated to laboratory
conditions for seven days prior to use in the experiments. At
the end of this period, each mouse was weighed and then re-
ceived 2 mL of liquid (containing the desired test agent) per
100 g body weight.
All animals were properly identified by numerical
markings on their tails to ensure continuity of the records
and reliable interpretation of the results throughout the
study (OECD, 1997c). After the period of treatment, the
mice were euthanized by inhalation of carbon dioxide in
adapted acrylic chambers as described in the Report of the
American Veterinary Medical Association panel on eutha-
nasia (Beaver et al., 2000). This study was done in accor-
dance with the Universal Declaration of Animal Rights
(UNESCO, 1978), the ethical principles for animal experi-
mentation established by the Brazilian Society of Labora-
tory Animal Science (SBCAL - Sociedade Brasileira de
Ciência em Animais de Laboratório), the Brazilian Envi-
ronmental Crimes Law (Law no. 9.605, February 12,
1998), the Brazilian standards for Didactic-Scientific Prac-
tice of Vivisection of Animals (Law no. 6.638, May 8,
1979), and was approved by the Committee for Ethics in
Research Involving Animals at UNIFENAS (CEPEAU
Protocol no. 04A/2008).
Experimental groups
The experimental groups of mice (3 males and 3 fe-
males each) were assessed 24 h and 48 h after a single treat-
ment administered by gavage (Figure 1). The mutagenic
activity of GEZJ was assessed in mice that received doses
of 0.5-2 g.kg-1 (groups 7-14) and the antimutagenic activity
was assessed in mice that received NEU (50 mg.kg-1) +
GEZJ (2 g.kg-1) (groups 15 and 16) and DXR (5 mg.kg-1) +
GEZJ (2 g.kg-1) (groups 17 and 18). The doses of GEZJ
were chosen based on previous acute toxicity experiments
in mice that yielded LD50 values of 2.0-3.5 g/kg for several
plant extracts, including Z. joazeiro (Alviano et al., 2008).
Negative controls (groups 1 and 2: 150 mM NaCl in type 1
water) and positive controls (groups 3 and 4: 50 mg.kg-1 of
NEU; groups 5 and 6: 5 mg.kg-1 of DXR) were also in-
cluded as single treatments administered by gavage (NaCl)
and intraperitoneally (NEU and DXR) (OECD, 1997c).
Processing of bone marrow
MN assays using bone marrow erythrocytes were
done 24 h and 48 h after treatment, using previously de-
scribed methodology (Schmid, 1976; Zambrano et al.,
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Figure 1 - Experimental protocol for assessing the mutagenic and antimutagenic activity of a glycolic extract of Z. joazeiro bark. T - treatment, E - eutha-
nasia and n - number of mice.
1982). Shortly after euthanasia, the femora were surgically
and aseptically removed and the mice were appropriately
discarded. Each femur was sectioned at the proximal end
and the contents of the spinal canal were washed with
1.5 mL of 150 mM NaCl and transferred to a 15 mL centri-
fuge tube. This material was resuspended with a Pasteur pi-
pette to ensure a homogenous distribution of bone marrow
cells. The suspension was then centrifuged at 1,000 rpm
(Bench centrifuge, model NT 810, Nova Técnica Ind. e
Com. de Equip. para Laboratório Ltda., Piracicaba, SP,
Brazil) for 5 min. The supernatant was discarded and the re-
sulting pellet was resuspended in 500 L of 150 mM NaCI
solution added 4% formaldehyde. The slides (two per ani-
mal) were prepared by smearing, dried at room temperature
for 24 h and stained with Leishman’s eosin methylene blue
dye [pure dye for 3 min followed by diluted dye in distilled
water (1:6) for 15 min] to differentiate polychromatic
erythrocytes (PCEs) from monochromatic erythrocytes
(NCEs).
PCEs were observed by light microscopy (Nikon
Eclipse E-200 microscope) at a magnification of 1000x,
counted (at least 2000 anucleated polychromatic erythro-
cytes per animal) with the aid of a digital cell counter
(Contador Diferencial CCS02, Kacil Indústria e Comércio
Ltda., PE, Brazil) and photographed using an 8.1 Mega-
pixel Digital Camera (DC FWL 150). The number of PCEs,
the number and frequency of MNPCEs and the ratio of
polychromatic to monochromatic erythrocytes (PCE/NCE)
were determined.
Statistical analysis
The data from the MN assay were analyzed by one-
way analysis of variance (ANOVA) using a 9 x 2 x 2 (treat-
ment x gender x time) factorial scheme followed by multi-
ple comparisons with the Tukey test ( = 0.05). All
analyses were done using SAS® version 9.2 computer soft-
ware.
Results and Discussion
Ziziphus joazeiro Mart. has been popularly used to
treat dandruff, rheumatism, flu, fever, chronic bronchitis,
gastric ulcers, indigestion, heartburn and headaches and to
clean teeth (Schuhly et al., 1999; Cartaxo et al., 2010). In
addition, Z. joazeiro has potential antifungal (Cruz et al.,
2007), antibacterial (Schuhly et al., 1999; Alviano et al.,
2008; Leal et al., 2010), antioxidant (Alviano et al., 2008)
and antipyretic (Nunes et al., 1987) activities, as well as
low toxicity (Alviano et al., 2008). This information partly
supports the popular use of Z. joazeiro for certain treat-
ments and agrees with ethnopharmacological studies de-
signed to select plants for bioactivity screening (Cruz et al.,
2007). In contrast, few studies have examined the muta-
genic and antimutagenic effects of Z. joazeiro Mart.
In the present study, the number and frequency of
MNPCEs and the PCE/NCE ratios in mouse bone marrow
were analyzed in mutagenic and antimutagenic assays of a
glycolic extract of Z. joazeiro bark (Table 1 and Figure 2).
Analysis of the MNPCEs revealed no significant differ-
ences between the 24 h and 48 h results for the negative
(NaCl) and positive (DXR and NEU) controls. However,
there were significant differences (p  0.05) between the
negative and positive controls at the two time intervals.
There were no differences between the negative controls
and the treatments with GEJZ (0.5-2 g.kg-1) or with GEJZ
(2 g.kg-1) + DXR (5 mg.kg-1): these responses showed no
dose or time dependence, but varied between male and fe-
male mice. Mice treated with GEJZ (2 g.kg-1) + NEU (50
mg.kg-1) had intermediate values (n and %) that differed
significantly from the negative and positive controls. These
results suggest absence of mutagenicity (clastogenicity
and/or aneugenicity) for GEZJ, regardless of the extract
dose and time interval, although the responses varied be-
tween sexes. In contrast, GEJZ (2 g.kg-1) showed anti-
mutagenic activity (anticlastogeny and/or antianeugeny)
towards the chemotherapeutic agent DXR (5 mg.kg-1) or
NEU (50 mg.kg-1), regardless of the time interval, although
once again intersex variation was observed. These findings
indicate that compounds in GEZJ can act against DXR-
induced mutagenic effects in mouse bone marrow. Such
compounds could include n-alkanes, triterpenoids [i.e.,
betulinic acid, alphitolic acid, ursolic acid, ester derivatives
of betulinic acid such as 7-(4-hydroxy-benzoylo-
xy)-betulinic acid, 7-(4-hydro-3-methoxy-benzoyloxy)-
betulinic acid and 27-(4-hydroxy-3-methoxy-benzoylo-
xy)-betulinic acid] (Oliveira et al., 2003; Schuhly et al.,
1999) and saponins (Alviano et al., 2008). DXR has been
reported to induce micronuclei, chromatid and chromo-
somal aberrations, and DNA single- and double-strand
breaks in vitro and in vivo (Bean et al., 1992; Al-Harbi,
1993; Al-Shabanah, 1993; Delvaeye et al., 1993; Jagetia
and Nayak, 1996, 2000; Shan et al., 1996; Dhawan et al.,
2003; Jagetia and Aruna, 2000). In addition, the major
acute toxicity induced by DXR is bone marrow suppres-
sion, while the long-term clinical usefulness is limited by a
cumulative, dose-dependent, irreversible, chronic cardio-
toxicity that manifests itself as congestive heart failure or
cardiomyopathy (Van Acker et al., 1995, 2000).
For the PCE/NCE ratio, there were no significant dif-
ferences between the negative controls (NaCl), the positive
control DXR (5 mg.kg-1), the GEZJ (0.5 mg.kg-1) group,
and mice treated with GEZJ (2 g.kg-1) + NEU (50 mg.kg-1)
or with GEZJ (2 g.kg-1) + DXR (5 mg.kg-1) (Table 1 and
Figure 1). For the treatments with GEZJ, there was a signif-
icant difference between the dose of 500 mg.kg-1 and the
doses of 1.5 g.kg-1 and 2 g.kg-1. Although there were no sig-
nificant intersex differences, the responses did vary with
time (24 h vs. 48 h). Lower doses of GEZJ (0.5-1 g.kg-1)
were not toxic to bone marrow compared to higher doses
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(1.5-2 g.kg-1), regardless of sex, but varied between time in-
tervals. Thus, the PCE/NCE ratio at higher doses was sig-
nificantly lower than observed in positive the controls
treated with NEU. These results suggest the absence of sys-
temic toxicity at GEZJ doses of 0.5-1 g.kg-1 and moderate
toxicity at doses of 1.5-2 g.kg-1, regardless of mouse gen-
der, with variable responses over time (24-48 h). Whereas
treatment with GEZJ (2 g.kg-1) + DXR (5 mg.kg-1) signifi-
cantly reduced the MNPCEs (n and %), there was a signifi-
cant increase in the PCE/NCE ratio with this same
treatment, indicating that this combination was not toxic to
mouse bone marrow. These results also suggest that the
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Figure 2 - Box-plots showing the MNPCE frequencies and PCE/NCE ratios in mouse bone marrow in mutagenic and antimutagenic assays of Z. joazeiro
bark. Means with different letters are significantly different (p  0.05). NaCl - control group treated with 150 mM NaCl, NEU - N-nitroso-N-ethylurea
(50 mg.kg-1), DXR - doxorubicin hydrochloride (5 mg.kg-1), GEZJ - Glycolic extract of Z. joazeiro Mart. bark (0.5-2 g.kg-1), GEZJ (2 g.kg-1) + NEU
(50 mg.kg-1) and GEZJ (2 g.kg-1) + DXR (5 mg.kg-1).
phytochemical compounds responsible for the moderate
toxicity (altered PCE/NCE ratio) of GEZJ (2 g.kg-1) in bone
marrow may also have an important role in attenuating the
mutagenicity (n and % of MNPCE) of DRX (5 mg.kg-1).
The acute toxicity of different plant extracts, includ-
ing Z. joazeiro, has previously been based on doses (1 to 4
or 5 g/kg) administered orally to different groups of mice
(one dose per mouse, with each group containing eight ani-
mals: four males and four females) (Alviano et al., 2008).
Behavioral parameters, including convulsion, hyperactiv-
ity, sedation, grooming, loss of righting reflex, increased or
decreased respiration, and changes in food and water intake
were also noted. These animals were observed and weighed
over a period of 14 days; no weight loss was detected.
Treated mice showed no behavioral alterations and the ex-
tract LD50 values ranged from 2.0-3.5 g/kg. None of the ex-
tracts was lethal to mice at the doses tested and the data
from the in vivo assays indicated that the extracts had low
toxicity (Alviano et al., 2008). The data from the MN as-
says presented here provides additional information on the
systemic toxicity of Z. joazeiro in mouse bone marrow
based on the PCE/NCE ratio that suggested moderate toxic-
ity of GEZJ at doses of 1.5-2 g.kg-1 that was independent of
mouse gender but varied with time (24-48 h).
The PCE/NCE ratio is an indicator of the acceleration
or inhibition of erythropoiesis and varies with the scoring
interval. A continuous decline in the PCE/NCE ratio may
reflect the inhibition of cell division, the killing of erythro-
blasts, the removal of damaged cells, or dilution of the ex-
isting cell pool with newly formed cells (Venkatesh et al.,
2007). Several mechanisms may contribute to the cytoto-
xicity of DXR and MN induction (Gewirtz, 1999), includ-
ing the intercalation of DXR in cellular DNA (Painter,
1978; Kiyomiya et al., 2001), stabilization of the topoi-
somerase II-DNA complex (Pommier et al., 1985; Guano
et al., 1999), free radical-mediated toxicity caused by redox
cycling of the semiquinone radical (Bachur et al., 1979), or
the formation of reactive oxygen species by the DXR-iron
complex (Eliot et al., 1984; Myers, 1998; Konorev et al.,
1999). On the other hand, chemicals such as captopril and
desferrioxamine (Al-Harbi, 1993; Al-Shabanah, 1993), -
carotene and vitamins A, C and E (Lu et al., 1996; Gulkac
et al., 2004; Costa and Nepomuceno, 2006), thiol N-acetyl-
cysteine, probucol, lovastatin and hydrophilic flavonoids
such as rutin and luteolin (Al-Gharably, 1996; Sadzuka et
al., 1997; D’Agostini et al., 1998; Bardeleben et al., 2002)
can also reduce DXR-induced MN formation, genotoxicity
and cytotoxicity. However, proponents of herbal medicine
always claim that mixtures are better than pure chemicals
because the dozens of biologically active compounds in
plants work together to produce a greater effect than any
one chemical on its own (Mackenzie, 2001).
Screening for newer pharmacological agents that can
protect normal cells against DXR-induced cumulative tox-
icity is essential. Many plants widely used in traditional
medicine are less toxic than pharmaceutical agents and
have recently attracted the attention of researchers around
the world. Plants contain many compounds and it is likely
that these can provide better protection than a single mole-
cule (Vidhya and Devraj, 1999). The presence of many
molecules in plants may be advantageous, as some of them
may counteract the toxicity of others so that the net effect
may be therapeutically beneficial. For example, the effect
of various concentrations (200, 250, 300, 350 and 400
mg/kg body weight) of Aegle marmelos on DXR-induced
mutagenicity in mouse bone marrow was studied (Ven-
katesh et al., 2007). Mice treated with different concentra-
tions of DXR (5, 10 or 15 mg.kg-1 body weight) showed a
dose-dependent elevation in the frequency of PCE and
NCE in their bone marrow, and this was accompanied by a
DXR-mediated dose-dependent decline in the PCE/NCE
ratio. In contrast, the treatment of mice with A. marmelos
orally once a day for five consecutive days before treatment
with DXR significantly reduced the frequency of DXR-
induced micronuclei and significantly increased the
PCE/NCE ratio at all time intervals. This chemoprotective
effect may reflect the sum of interactions between different
components of this complex mixture. The degree of protec-
tion may depend on the individual or collective interaction
of components with the genotoxic agent. The plausible
mechanisms of action of A. marmelos in protecting against
DXR-induced damage included the scavenging of O2
•-, •OH
and other free radicals, an increase in antioxidant status,
restoration of topoisomerase II activity and inhibition of the
formation of the DXR-iron complex (Venkatesh et al.,
2007). More recently, Alves et al. (2012) evaluated the
genotoxic potential of a hydroalcoholic extract of
Copaifera lansdorffii Desf. leaves and its influence on the
genotoxicity of DXR (MN test) in peripheral blood from
Swiss mice. Their finidngs demonstrated that C. lansdorffii
Desf. was not genotoxic but that the extract significantly re-
duced the number of micronuclei in DXR-treated mice. The
putative antioxidant activity of one or more of the active
compounds of C. lansdorffii Desf., including two major
flavonoid heterosides (quercitrin and afzelin), may explain
the effect of this plant on DXR genotoxicity.
Conclusions
This study used the MN assay to evaluate the muta-
genic (clastogeny and/or aneugeny) and antimutagenic ac-
tivity of an extract of Z. joazeiro bark in mouse bone
marrow. The Z. joazeiro bark extract was not mutagenic at
the doses and time intervals tested, although sex-related
variation was observed. The antimutagenic effect (anti-
clastogeny and/or antianeugeny) of Z. joazeiro bark extract
against DXR-induced genotoxicity was observed at a high
dose of extract (2 g.kg-1), but was independent of the dura-
tion of treatment and animal sex. Low concentrations of
GEZJ (0.5-1 g.kg-1) were not toxic, regardless of mouse
gender and duration of treatment, whereas moderate toxic-
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ity was observed at doses of 1.5-2 g.kg-1. Together, these
findings indicate that phytochemical compounds in Z.
joazeiro bark can attenuate DRX-induced mutagenicity and
that a high dose of extract (2 g.kg-1) showed no toxicity in
the conditions tested here.
Other studies on the genotoxicity and mutagenicity of
Z. joazeiro extracts are needed to characterize the
(anti)genotoxic effects and mechanisms, and to determine
the potential health risks of this extract in humans. Such in-
vestigations will be useful for implementing strategies re-
lated to the use of Z. joazeiro bark in chemoprevention.
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